NT5E and cancer: Clinical trials of anti-CD73 monoclonal antibodies, CD73 inhibitors, and adenosine receptor antagonists listed in the National Cancer Institute Drug Dictionary (www.cancer.gov/publications/dictionaries/cancer-drug/) are underway in patients with advanced solid cancers.